


Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) Compound A compound in the form of pure an enantiomer or in the form of a mixture of enantiomers, ~~complying with the general~~ having the formula (I)



in which R represents a halogen atom or a (C₃-C₆)cycloalkyl group or a phenyl group substituted by one or more groups chosen from a halogen atom, or a (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino, (C₁-C₃)dialkylamino, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, acetyl or methylenedioxy group, or a piperidinyl, or morpholin-4-yl, or pyrrolidin-1-yl, or azetidin-1-yl, or azepin-1-yl, or pyridinyl, or quinolinyl, or thienyl, or pyrazinyl, or furyl, or benzofuryl, or benzothienyl, or indolyl, or pyrimidinyl, or isoxazolyl, or phenoxazinyl, or phenoxathiinyl phenoxathienyl, or dibenzothienyl, or dibenzofuryl, or pyrrolyl, or naphthyl group, where each of these groups may optionally be substituted by one or more groups chosen from halogen atoms, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxy, amino, (C₁-C₃)dialkylamino or (C₃-C₈)cycloalkylamino groups, and where, of the two carbon-carbon bonds represented by —, one is a single bond and the other may be is either a single bond or a double bond,
in the form of base or of salt derived from addition to an acid or a salt thereof.

2. (currently amended) Compound The compound according to Claim 1 wherein R either represents a halogen atom or a phenyl group substituted by one or more groups chosen from halogen atoms and (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino,

trifluoromethyl, cyano, hydroxy, acetyl or methylenedioxy groups, or represents a pyridinyl group or a thienyl group or an indolyl group or a pyrimidinyl group optionally substituted by one or more (C₁-C₆)alkoxy groups.

3. **(currently amended)** A method for the treatment or prevention of disorders linked to a dysfunction of the nicotinic receptors of a disorder selected from the group consisting of detrimental memory and attentional changes, Alzheimer's disease, Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises administering to a patient in need of such said treatment an effective amount of a compound according to Claim 1.

4. **(previously presented)** Pharmaceutical composition which comprises a compound according to Claim 1, together with an excipient.

5. **(currently amended)** A method for the treatment or prevention of disorders linked to a dysfunction of the nicotinic receptors of a disorder selected from the group consisting of detrimental memory and attentional changes, Alzheimer's disease, Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises administering to a patient in need of such said treatment an effective amount of a compound according to Claim 2.

6. **(original)** Pharmaceutical composition which comprises a compound according to Claim 2, together with an excipient.